Fig. 2.

XBF attenuated LPS-induced inflammation in RAW264.7 cells. (A) qRT-PCR determination of the mRNA expression of IL-1β, IL-6, and TNF-α in RAW264.7 cells upon treatment with XBF (2 and 3 mg/ml) for 24 h. (B) Concentration of IL-1β, IL-6 and TNF-α in cell culture medium was examined by ELISA assay, and data presented were normalized by the concentration of protein lysates. (C) RAW264.7 cells were treated with XBF (0.5, 1, 2, 3 and 4 mg/ml) for 24 h. Cell viability was measured by the CCK-8 assay. (D-E) qRT-PCR determination of the mRNA expression of CD80, CD86, iNOS, CD163, CD206, and Arg-1 in RAW264.7 cells upon treatment with XBF (2 and 3 mg/ml) for 24 h. (F) RAW264.7 cells were treated with XBF (2 and 3 mg/ml) for 24 h, the expression of both phosphorylated and total IκKα, IκBα, NF-κB, P38, and Erk were determined by western blotting. β-Actin was used as an internal control. Data are presented as the mean ± SE from three independent experiments. ^#p < 0.05; ^##p < 0.01; ^###p < 0.001 compared with untreated cells; *p < 0.05; **p < 0.01; ***p < 0.001 compared with LPS-treated cells.